Published in JAKSTAT on June 16, 2014
New insights in prolactin: pathological implications. Nat Rev Endocrinol (2015) 0.98
JAK2 activation by growth hormone and other cytokines. Biochem J (2015) 0.85
Solution structure of the transmembrane domain of the mouse erythropoietin receptor in detergent micelles. Sci Rep (2015) 0.81
Cell non-autonomous regulation of hepatic IGF-1 and neonatal growth by Kinase Suppressor of Ras 2 (KSR2). Sci Rep (2016) 0.77
Regulation of Long Bone Growth in Vertebrates; It Is Time to Catch Up. Endocr Rev (2015) 0.75
Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor. Diabetes Metab Syndr Obes (2015) 0.75
Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science (1992) 7.00
STATs: signal transducers and activators of transcription. Cell (1996) 6.10
Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature (1988) 4.40
Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell (1993) 3.54
Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science (1991) 3.24
Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science (2014) 2.52
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol (1991) 2.47
Rational design of potent antagonists to the human growth hormone receptor. Science (1992) 2.45
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood (2005) 2.41
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol (2011) 2.20
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A (2001) 2.00
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol (2005) 1.83
Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol (1998) 1.79
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem (2007) 1.55
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood (2005) 1.50
The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev (2004) 1.46
The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol (2010) 1.44
Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol (2006) 1.39
Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol Endocrinol (2006) 1.31
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol (2012) 1.25
Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci U S A (2002) 1.22
Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol (2001) 1.19
Evolution of Class I cytokine receptors. BMC Evol Biol (2007) 1.12
Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J (2011) 1.00
An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol (2008) 0.97
Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization. Proc Natl Acad Sci U S A (2003) 0.95
Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab (2001) 0.94
Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation. J Biol Chem (2000) 0.94
Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. Mol Endocrinol (2007) 0.93
Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J Biol Chem (1998) 0.89
The role of receptor dimerization domain residues in growth hormone signaling. J Biol Chem (1997) 0.87
Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity. Mol Endocrinol (2010) 0.87
Epitope map for a growth hormone receptor agonist monoclonal antibody, MAb 263. Mol Endocrinol (2003) 0.87
Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation. Proteins (2010) 0.86
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochem J (2014) 0.83
Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping. Endocrinology (2011) 0.82
Growth hormone receptor: structure function relationships. Horm Res Paediatr (2011) 0.81